PT2921500T - Linhas de células assassinas naturais humanas modificadas geneticamente - Google Patents

Linhas de células assassinas naturais humanas modificadas geneticamente

Info

Publication number
PT2921500T
PT2921500T PT151509841T PT15150984T PT2921500T PT 2921500 T PT2921500 T PT 2921500T PT 151509841 T PT151509841 T PT 151509841T PT 15150984 T PT15150984 T PT 15150984T PT 2921500 T PT2921500 T PT 2921500T
Authority
PT
Portugal
Prior art keywords
natural killer
killer cell
cell lines
genetically modified
modified
Prior art date
Application number
PT151509841T
Other languages
English (en)
Original Assignee
The Institute For Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35968029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2921500(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Institute For Cancer Res filed Critical The Institute For Cancer Res
Publication of PT2921500T publication Critical patent/PT2921500T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
PT151509841T 2004-07-10 2005-07-08 Linhas de células assassinas naturais humanas modificadas geneticamente PT2921500T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58658104P 2004-07-10 2004-07-10

Publications (1)

Publication Number Publication Date
PT2921500T true PT2921500T (pt) 2023-09-25

Family

ID=35968029

Family Applications (1)

Application Number Title Priority Date Filing Date
PT151509841T PT2921500T (pt) 2004-07-10 2005-07-08 Linhas de células assassinas naturais humanas modificadas geneticamente

Country Status (12)

Country Link
US (8) US7618817B2 (pt)
EP (5) EP2112162B1 (pt)
AT (1) ATE443084T1 (pt)
AU (1) AU2005277831B2 (pt)
CA (2) CA2572938C (pt)
DE (1) DE602005016683D1 (pt)
DK (4) DK2801583T3 (pt)
ES (3) ES2925912T3 (pt)
HK (2) HK1203975A1 (pt)
PL (1) PL2921500T3 (pt)
PT (1) PT2921500T (pt)
WO (1) WO2006023148A2 (pt)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2801583T3 (en) * 2004-07-10 2018-07-16 Fox Chase Cancer Center Genetically modified human natural killer cell lines
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
WO2008031056A2 (en) 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CN101861168B (zh) 2007-05-07 2014-07-02 米迪缪尼有限公司 抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用
JP5282040B2 (ja) * 2007-09-28 2013-09-04 オリンパス株式会社 Ｆｃ受容体遺伝子導入ＮＫ細胞を用いた抗体依存性細胞傷害のアッセイ方法
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
CA2708871C (en) 2007-12-21 2017-11-21 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r.alpha.) - 173
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
EP2358392B1 (en) 2008-11-12 2019-01-09 MedImmune, LLC Antibody formulation
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
ES2719495T3 (es) 2012-05-07 2019-07-10 Dartmouth College Anticuerpo dirigido contra b7-h6, proteínas de fusión, y métodos de uso de los mismos
ES2837392T3 (es) 2013-10-02 2021-06-30 Medimmune Llc Anticuerpos anti-influenza A neutralizantes y usos de los mismos
EP3062800B1 (en) 2013-11-01 2020-04-08 Nantkwest, Inc. Tumoricidal compositions
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
EP4227318A1 (en) 2014-03-28 2023-08-16 Regents of the University of Minnesota Polypeptides, cells, and methods involving engineered cd16
EP3143134B1 (en) 2014-05-15 2020-10-28 National University of Singapore Modified natural killer cells and uses thereof
US20170182292A1 (en) 2014-05-22 2017-06-29 Nantkwest, Inc. Treating solid tumours with nk-92 cells applied by microcatheter
WO2015179833A1 (en) * 2014-05-23 2015-11-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating antibody resistance
KR20170018450A (ko) 2014-06-18 2017-02-17 케모테라포이티쉐스 포르슝스인스티투트 게오르크-스파이어-하우스 세포 치료제로서의 car-발현 nk-92 세포
WO2016057345A1 (en) * 2014-10-06 2016-04-14 Nantkwest, Inc. Treating viral hemorrhagic fever with nk-92 cells
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
EP3273977A4 (en) * 2015-03-27 2018-12-05 Nantkwest, Inc. Nk-92 cells in combination therapy with cancer drugs
IL287051B (en) * 2015-03-27 2022-09-01 Immunitybio Inc nk-2 cells and genetically engineered monoclonal antibodies for cancer treatment
CN108136021A (zh) 2015-04-25 2018-06-08 综合医院公司 用于治疗癌症的抗驱走性试剂和抗癌剂联合疗法和组合物
MX2017015189A (es) 2015-06-01 2018-04-13 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
CN107709552B (zh) 2015-06-10 2022-05-13 南克维斯特公司 用于治疗癌症的修饰的nk-92细胞
ES2701338T3 (es) * 2015-07-29 2019-02-21 Onkimmune Ltd Células asesinas naturales modificadas y líneas de células asesinas naturales que tienen mayor citotoxicidad
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
EP3349797A4 (en) 2015-09-18 2019-06-12 The General Hospital Corporation Dba Massachusetts General Hospital LOCALIZED DELIVERY OF ANTICHIMIOREPULSION AGENT FOR THE TREATMENT OF CANCER
US10533157B1 (en) 2015-12-03 2020-01-14 Nantbio, Inc. Recombinant NK cells expressing co-stimulatory molecules
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
WO2017132202A1 (en) * 2016-01-25 2017-08-03 Nant Holdings Ip, Llc Nk cells with altered cxcl12/cxcr4 signaling
WO2017184534A1 (en) * 2016-04-18 2017-10-26 The Gorlin Companies Methods and compositions for improving safety and efficacy of natural killer cell immunotherapy
CN109689694B (zh) 2016-05-19 2022-11-22 通用医疗公司 与其受体IL-2Rβ结合的IL2作为用来增强自然杀伤细胞和调节性T细胞活性的平台
US11419894B2 (en) * 2016-09-16 2022-08-23 The General Hospital Corporation Modified natural killer cells for the treatment of cancer
WO2018064594A2 (en) 2016-09-29 2018-04-05 Nantkwest, Inc. Hla class i-deficient nk-92 cells with decreased immunogenicity
WO2018129199A1 (en) 2017-01-04 2018-07-12 Nova Southeastern University Natural killer (nk) cells expressing an antigen-specific functional t cell receptor (tcr) complex, methods for production thereof, and methods for therapeutic use thereof
US20200123503A1 (en) 2017-01-06 2020-04-23 Nantkwest, Inc. Genetically modified nk-92 cells with decreased cd96/tigit expression
CA3051866A1 (en) * 2017-02-01 2018-08-09 Nant Holdings Ip, Llc Calreticulin-mediated cancer treatment
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
JP2020507349A (ja) * 2017-02-09 2020-03-12 インダプタ セラピューティクス インコーポレイテッド 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法
CN110582288A (zh) 2017-02-28 2019-12-17 恩多塞特公司 用于car t细胞疗法的组合物和方法
CN116440293A (zh) 2017-03-08 2023-07-18 免疫生物公司 用于临床的修饰的NK-92 haNK003细胞
JP2020515542A (ja) 2017-03-23 2020-05-28 ザ ジェネラル ホスピタル コーポレイション Ｃｘｃｒ４／ｃｘｃｒ７の遮断およびヒトパピローマウイルス関連疾患の治療
EP3601538A4 (en) * 2017-03-27 2021-03-10 Nantcell, Inc. ANK AND IL-12 COMPOSITIONS AND METHODS
US11896616B2 (en) 2017-03-27 2024-02-13 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
SG11201908492PA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
US20200306302A1 (en) 2017-08-04 2020-10-01 Nantkwest, Inc. Treating and inhibiting leukemia with nk-92 cells
WO2019084388A1 (en) * 2017-10-26 2019-05-02 Regents Of The University Of Minnesota RECOMBINANT IMMUNE CELLS, METHODS OF MANUFACTURE AND METHODS OF USE
WO2019084284A1 (en) 2017-10-27 2019-05-02 Coneksis, Inc. NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
US20210187024A1 (en) 2017-11-01 2021-06-24 Nantkwest, Inc. NK-92 Cells to Stimulate Anti-Cancer Vaccine
BR112020014913A2 (pt) 2018-01-22 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Métodos para uso de células t car
US20210040451A1 (en) 2018-01-31 2021-02-11 Nantkwest, Inc. Use of 5% human albumin in wash and harvest media
EP3743446A1 (en) 2018-03-12 2020-12-02 Nantkwest, Inc. Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
US20190321402A1 (en) * 2018-04-19 2019-10-24 Onkimmune Limited Nk cells for use with anitbodies in cancer therapy
JP2021522839A (ja) * 2018-05-14 2021-09-02 インダプタ セラピューティクス インコーポレイテッド 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット
WO2019226649A1 (en) 2018-05-22 2019-11-28 Nantkwest, Inc. Optimization of nk-92 cell growth using poloxamer
CN112166183A (zh) 2018-05-22 2021-01-01 南克维斯特公司 用于生长nk92细胞的基础培养基
US20210163868A1 (en) 2018-05-22 2021-06-03 Nantkwest, Inc. Methods and systems for cell bed formation during bioprocessing
IL278857B1 (en) * 2018-05-22 2024-05-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for EPSILON–FC and uses thereof
US20210267190A1 (en) 2018-07-10 2021-09-02 Nantkwest, Inc. Cryopreservation
WO2020028654A1 (en) 2018-08-01 2020-02-06 Nantkwest, Inc. Combined invasion and cytotoxicity assay using chemokine secreting target cells
WO2020028656A1 (en) 2018-08-01 2020-02-06 Nantkwest, Inc. A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies
JP2021524732A (ja) 2018-10-31 2021-09-16 ナントケーウエスト，インコーポレイテッド Ｃｄ１９−ｃａｒを発現するｎｋ細胞によるｃｄ１９陽性リンパ悪性腫瘍の排除
CA3094111C (en) 2018-10-31 2024-02-20 Nantkwest, Inc. Elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells
US11547727B2 (en) 2018-11-06 2023-01-10 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
US20220017594A1 (en) 2018-11-26 2022-01-20 Nantkwest, Inc. Il-2 dependent nk-92 cells with stable fc receptor expression
JP2022514086A (ja) * 2018-12-20 2022-02-09 クレオ ファーマシューティカルズ， インコーポレイテッド Ａｒｍおよびナチュラルキラー細胞の併用療法
US20220073878A1 (en) * 2019-01-18 2022-03-10 Acepodia Biotechnologies Ltd. A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell
WO2020188570A1 (en) * 2019-03-19 2020-09-24 Ramot At Tel-Aviv University Ltd. T cell expressing an fc gamma receptor and methods of use thereof
CN113677791A (zh) 2019-03-21 2021-11-19 昂克医疗有限公司 对细胞死亡具有增加的抗性的经修饰的免疫效应细胞
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
AU2020261039A1 (en) 2019-04-23 2021-12-09 Sanofi Anti-CD38 antibodies and formulations
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CA3115917A1 (en) * 2019-08-01 2021-02-04 Nantkwest, Inc. Anti-b7-h4 chimeric antigen receptor-modified nk-92 cells
US20220289824A1 (en) 2019-08-15 2022-09-15 Nantbio, Inc. TGF-beta TRAP
WO2021101467A1 (en) * 2019-11-19 2021-05-27 Acibadem Mehmet Ali̇ Aydinlar Üni̇versi̇tesi̇ A method for redesign and expansion of nk92 cells for use in immunotherapy
GB2604813A (en) * 2019-11-20 2022-09-14 Immunitybio Inc Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
EP3914699A4 (en) * 2019-12-09 2023-03-29 ImmunityBio, Inc. SCREENING OF CELLULAR CLONES EXPRESSING POLYGENIC TRANSGENES BY POSITIVE SELECTION NOT DEPENDENT ON ANTIBIOTICS
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
EP4097219A4 (en) * 2020-01-28 2023-10-11 ImmunityBio, Inc. CHIMERIC ANTIGEN RECEPTOR MODIFIED NK-92 CELLS TARGETING SUPERFAMILY RECEPTORS
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
CN113603787B (zh) * 2020-05-04 2023-05-23 英诺康生物医药科技(广州)有限公司 一种非分泌型的人白细胞介素15及应用
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
US20220401485A1 (en) * 2020-08-11 2022-12-22 Immunitybio, Inc. Chimeric Antigen Receptor-Modified NK-92 Cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2
EP4108247A1 (en) 2021-06-23 2022-12-28 Ostravska univerzita Urine progenitor cells for use in cancer therapy
WO2023081163A1 (en) 2021-11-02 2023-05-11 Immunitybio, Inc. Natural killer cells for chordoma therapy
EP4180049A1 (en) 2021-11-16 2023-05-17 Ostravska univerzita Therapeutic composition for cancer treatment
US20230323395A1 (en) * 2021-12-15 2023-10-12 Homology Medicines, Inc. Methods and compositions for the production of adeno-associated virus

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3733919A (en) * 1971-09-20 1973-05-22 Adjustable eccentric bearing mountings background
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
ES2262163T3 (es) 1988-05-27 2006-11-16 Applied Research Systems Ars Holding N.V. Receptor iii de fc gamma humano.
US5767077A (en) 1988-05-27 1998-06-16 Applied Research Systems Ars Holding N.V. Human Fc-γ receptor III
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US7038031B1 (en) 1989-07-28 2006-05-02 Sloan-Kettering Institute For Cancer Research DNA encoding FcγR receptor protein on NK cells
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
NZ285395A (en) 1994-05-02 1998-10-28 Novartis Ag Chimeric antibody, cancer treatment
KR100343214B1 (ko) * 1995-03-28 2002-11-13 삼성에스디아이 주식회사 전계방출소자의제조방법
US5830725A (en) 1995-04-28 1998-11-03 The Board Of Trustees For The Leland Stanford Junior University Rapid, stable high-titre production of recombing retrovirus
US6458939B1 (en) 1996-03-15 2002-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
WO1998049268A1 (en) * 1997-04-30 1998-11-05 Hans Klingemann Natural killer cell lines and methods of use
US20030026780A1 (en) * 2001-07-18 2003-02-06 Hood Leroy E. Innate immunity mediated methods of treating pathological conditions
US20050031613A1 (en) * 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
US7618617B2 (en) * 2002-05-31 2009-11-17 L'oreal Aqueous hair treatment compositions, thickened with an amphiphilic linear block copolymer
MXPA05013923A (es) 2003-07-02 2006-08-11 Univ Genova Anticuerpos nk receptores de pan-kir2dl y su utilizacion en diagnostico y terapia.
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
DK2801583T3 (en) 2004-07-10 2018-07-16 Fox Chase Cancer Center Genetically modified human natural killer cell lines
PT1836225E (pt) 2005-01-06 2012-01-10 Novo Nordisk As Agentes de ligação a kir e métodos de utilização dos mesmos

Also Published As

Publication number Publication date
ES2955952T3 (es) 2023-12-11
EP1771471A2 (en) 2007-04-11
US20160067356A1 (en) 2016-03-10
US20230372545A1 (en) 2023-11-23
US20080247990A1 (en) 2008-10-09
WO2006023148A8 (en) 2006-05-04
ATE443084T1 (de) 2009-10-15
US20100086996A1 (en) 2010-04-08
EP1771471B1 (en) 2009-09-16
AU2005277831B2 (en) 2012-11-22
US20240016957A1 (en) 2024-01-18
CA2572938A1 (en) 2006-03-02
US20100086486A1 (en) 2010-04-08
EP3406631B1 (en) 2022-06-29
US9181322B2 (en) 2015-11-10
DE602005016683D1 (de) 2009-10-29
AU2005277831A1 (en) 2006-03-02
EP2112162B1 (en) 2015-01-14
EP2921500A1 (en) 2015-09-23
CA3052445C (en) 2023-08-22
DK2921500T3 (da) 2023-09-18
US20130040386A1 (en) 2013-02-14
ES2678094T3 (es) 2018-08-08
EP2801583B1 (en) 2018-04-25
US20060292156A1 (en) 2006-12-28
EP2112162A1 (en) 2009-10-28
AU2005277831A2 (en) 2009-03-12
US8313943B2 (en) 2012-11-20
DK2801583T3 (en) 2018-07-16
ES2925912T3 (es) 2022-10-20
CA2572938C (en) 2019-10-15
PL2921500T3 (pl) 2024-02-05
DK3406631T3 (da) 2022-08-29
DK2112162T3 (da) 2015-02-23
HK1215269A1 (zh) 2016-08-19
EP3406631A1 (en) 2018-11-28
HK1203975A1 (en) 2015-11-06
US9150636B2 (en) 2015-10-06
EP2801583A1 (en) 2014-11-12
US7618817B2 (en) 2009-11-17
WO2006023148A3 (en) 2006-08-03
EP2921500B1 (en) 2023-08-30
CA3052445A1 (en) 2006-03-02
WO2006023148A2 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
HK1215269A1 (zh) 基因修飾的人自然殺傷細胞系
WO2005007121A3 (en) Mutant interleukin-2(il-2) polypeptides
DK1639013T3 (da) Pan-kir2dl-nk-receptor-antistoffer og anvendelse heraf til diagnosticering og terapi
IL186986A0 (en) Compositions and methods for modulating immune responses
DK1645626T3 (da) Cellelinie
AU2005211385A1 (en) Modified human growth hormone polypeptides and their uses
GB0304068D0 (en) Substances
SG166090A1 (en) Il-13 binding agents
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
GB2436266A (en) Modified human growth hormone
ATE475669T1 (de) Einen modifizierten t-zellen-rezeptor exprimierende zellen
WO2006029010A3 (en) Methods of activating nkt cells
DK1565183T3 (da) Rapamycin og IL-10 til behandling af autoimmune sygdomme
AU2002356601A1 (en) Bispecific anti-cd19 x anti-cd16 antibodies and uses thereof
EP1589998A4 (en) USES OF MAMMALIAN CYTOKINE AND RELATED REAGENTS
GT200300199A (es) Indoles 2,7-sustituidos
CA2466778A1 (en) Flexible seat mount for chair seat bottom
AU2002364302A1 (en) Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
ATE412010T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
WO2005001042A8 (en) Smooth muscle progenitor cells
ATE144791T1 (de) Innerhalb des alpha-locus gelegenes t-zell- rezeptor-gen und dna-konstruktionen
GB2430136A (en) Personal accessory carrier
DE602004013291D1 (de) Dendritische zelle mit alpha-glycosylceramid-derivat und antigen zur verwendung bei der unterdrückung von immunreaktionen
Grosholz et al. OOS 18-4: The importance of propagule source region as a component of propagule pressure for marine invasions
TR200402060U (tr) Güneş şemsiyesinin sabitlenmesi için su doldurulabilen bidon.